? Botulinum neurotoxin, an NIAID class A agent, has been weaponized, thus dictating an urgent need for a safe, efficacious vaccine that will protect against all seven known serotypes of the toxin. The two specific aims of this project are first, the fast-track development (within one-to-two years) of a safe and efficacious pentavalent vaccine for the neurotoxin that will provide immunologic protection against toxin serotypes A, B, C, E and F; and second, development of a fully protective heptavalent vaccine to include serotypes D and G within five years. The partners for this project include representatives from industry (DynPort Vaccine Company LLC:DVC), academe (University of Nebraska-Lincoln: UNL and the University of Colorado Health Sciences Center: UC-HSC) and the military (U.S. Army Medical Research Institute of Infectious Diseases: USAMRIID). The approach we will take to achieve these aims is based upon the successful development and expression in the yeast, P. pastoris, of serotype-specific toxin heavy-chain protein fragments, that, when purified and administered to experimental animals, provide protective immunity against challenge with lethal doses of the botulinum neurotoxins. Monovalent vaccine candidates against serotypes A and B are already in current Good Manufacturing Practices pilot production, and vaccine candidates for serotypes C, E and F are in advanced stages of process development at UNL, thus facilitating the likelihood of success of the first specific aim. The methodologies established for development of vaccine candidates against serotypes A, B, C, E and F provide a rich body of knowledge on which the development of equivalent vaccine candidates for the remaining two serotypes (D and G) will be based, thus facilitating accomplishment of the second specific aim. UC-HSC will contribute expertise in formulating and stabilizing both liquid and lyophilized vaccines, essential for the achievement of both specific aims. The proposed research will have a high probability of success, in part, because of the highly innovative approach of having the industry partner, DVC, whose business model is vaccine development through management and coordination of scientific subcontractors, serve as the lead institution. The impact of the successful completion of the project will be an effective heptavalent vaccine for prophylactic immune defense against botulinum neurotoxin within an expedited, but realistic, timeframe and elimination of botulinum toxin as a weapon of mass destruction. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI056514-02
Application #
6795978
Study Section
Special Emphasis Panel (ZAI1-ALR-M (M4))
Program Officer
Van de Verg, Lillian L
Project Start
2003-09-01
Project End
2008-02-29
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
2
Fiscal Year
2004
Total Cost
$3,134,091
Indirect Cost
Name
Dynport Vaccine Company, LLC
Department
Type
DUNS #
014130053
City
Frederick
State
MD
Country
United States
Zip Code
21702
Bai, Shujun; Manning, Mark Cornell; Randolph, Theodore W et al. (2011) Aggregation of recombinant human botulinum protein antigen serotype C in varying solution conditions: implications of conformational stability for aggregation kinetics. J Pharm Sci 100:836-48
Dux, Michael P; Huang, Jicai; Barent, Rick et al. (2011) Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(H(c))] expressed in Pichia pastoris. Protein Expr Purif 75:177-85
Clausi, Amber L; Morin, Andrea; Carpenter, John F et al. (2009) Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine. J Pharm Sci 98:114-21
Estey, Tia; Vessely, Christina; Randolph, Theodore W et al. (2009) Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. J Pharm Sci 98:2994-3012
Vessely, Christina; Estey, Tia; Randolph, Theodore W et al. (2009) Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J Pharm Sci 98:2970-93
Clausi, Amber L; Merkley, Scott A; Carpenter, John F et al. (2008) Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. J Pharm Sci 97:2049-61
Clausi, Amber; Cummiskey, Jessica; Merkley, Scott et al. (2008) Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci 97:5252-62
Roy, Shouvik; Henderson, Ian; Nayar, Rajiv et al. (2008) Effect of pH on stability of recombinant botulinum serotype A vaccine in aqueous solution and during storage of freeze-dried formulations. J Pharm Sci 97:5132-46
Vessely, Christina; Estey, Tia; Randolph, Theodore W et al. (2007) Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants. J Pharm Sci 96:2375-89
Huang, Jicai; Barent, Rick; Inan, Mehmet et al. (2007) Purification of the N- and C-terminal subdomains of recombinant heavy chain fragment C of botulinum neurotoxin serotype C. Methods Mol Biol 389:77-98

Showing the most recent 10 out of 12 publications